A phase I trial and three phase I/II trials have shown that tepotinib is safely administered and has promising activity in patients with MET+ hepatocarcinoma and EGFR+ NSCLC progressing to TKIs and that developed MET OE or AMP [80,81,82,83]. This evidence concerns the gene MET and non-small cell lung carcinoma.